



Docket No. 58614 (71432)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: B. Hansen et al.

Serial No.: 10/776,933

GROUP: Unknown

Filed: February 10, 2004

For: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN
EXPRESSION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this Completion of Filing Requirements and the papers indicated as being transmitted therewith is being deposited with the United States Postal Service on this date **July 12, 2004**, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EV438993372US**, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mail Stop PCT.

Lee Dunkle

(type or print name of person mailing paper)



(Signature of person mailing paper)

WARNING: *Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.*

***WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).*

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

 X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

- _____ (2) within three months of the mailing date of the Search Report issued by the
European Patent Office (dated _____) (**COPY ENCLOSED**); or
- _____ (3) after the period defined in (1) but before the mailing date of a **Final
Rejection or Notice of Allowance**, and the requisite Certification or fee
under Rule 1.17(p), namely **\$180.00**, is included herein; or
- _____ (4) after the mailing date of a **Final Rejection or Notice of Allowance** but
before the payment of the **Issue Fee**, and the requisite Certification,
petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s)
PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):


- X are enclosed herewith; or
- _____ have been cited in the parent application, and are thus not being resubmitted
herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is
authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments
should be credited to said Deposit Account.

Respectfully submitted,



Christine C. O'Day (Reg. 38,256)
Edwards & Angell, LLP
P.O. Box 55874
Boston, MA 02205
(617) 439-4444

Date: July 12, 2004



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			DOCKET NO.: 58614 (71432)		SERIAL NO.: 10/776,933		
			APPLICANT(S): B. Hansen et al.				
			FILING DATE: February 10, 2004		GROUP NO.: Unknown		
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	AA	WO 03/006475 A3	01/23/03	WIPO			
	AB	WO 02/28875 A2	04/11/02	WIPO			
	AC	WO 02/094250 A2	11/28/02	WIPO			
	AD	WO 00/66604	11/09/00	WIPO			
	AE	WO 00/56748	09/28/00	WIPO			
	AF	WO 00/56746	09/28/00	WIPO			
	AG	WO 00/12524	03/09/00	WIPO			
	AH	WO 99/38963	08/05/99	WIPO			
	AI	WO 99/14226	03/25/99	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	AJ	Yokomizo et al., <i>Cancer Res.</i> 55:4293-4296 (1995).					
	AK	Kahlos et al., <i>Int. J. Cancer</i> 20:95:198-204 (2001).					
	AL	Holmgren., <i>J. Biol. Chem.</i> 264(24):13963-13966 (1989).					
	AM	Holmgren, <i>Ann. Rev. Biochem.</i> 54:237-271 (1985).					
	AN	Powis, et al., <i>Annu. Rev. Biophys. Biomol. Struct.</i> 30:421-455 (2001).					
	AO	Gasdaska et al., <i>Biochim. Biophys. Acta</i> 1218:292-296 (1994).					
	AP	Matthews, et al., <i>Nucleic Acids Res.</i> 20(15):3821-3830 (1992).					
	AQ	Cromlish et al., <i>J. Biol. Chem.</i> 264(30):18100-18109 (1989).					
	AR	Bannister et al., <i>Oncogene</i> 6:1243-1250 (1991).					
	AS	Ueno, et al., <i>J. Biol. Chem.</i> 274(50):35809-35815 (1999).					
	AT	Grippio, et al., <i>J. Biol. Chem.</i> 258(22):13658-13664 (1983).					
	AU	Abate et al., <i>Science</i> 249:1157-1161 (1990).					
	AV	Welsh et al., <i>Cancer Res.</i> 62:5089-5095 (2002).					
	AW	Gasdaska et al., <i>Cell Growth Differ.</i> 6:1643-1650 (1995).					
	AX	Schenk et al., <i>J. Immunol.</i> 156:765-771 (1996).					
	AY	Taniguchi et al., <i>Nucleic Acids Res.</i> 24(14):2746-2752 (1996).					
	AZ	Rubartelli et al., <i>J. Biol. Chem.</i> 267(34):24161-24164 (1992).					
	BA	Nakamura et al., <i>Cancer</i> 69(8):2091-2097 (1992).					
	BB	Baker et al., <i>Cancer Res.</i> 57:5162-5167 (1997).					
	BC	Oblong et al., <i>J. Biol. Chem.</i> 269(16):11714-11720 (1994).					
	BD	Grogan et al., <i>Hum. Pathol.</i> 31(4):475-481 (2000).					
	BE	Soini, et al. <i>Clin. Cancer Res.</i> 7:1750-1757 (2001).					
	BF	Fujii et al., <i>Cancer</i> 68:1583-1591 (1991).					
	BG	Nakamura et al., <i>Cancer Detect. Prev.</i> 24(1):53-60 (2000).					
	BH	Hariharan et al., <i>Elsevier Science B.V.</i> 173: 265-270 (1996).					
Examiner:					Date:		